Cardiovascular disease: risk assessment and reduction, including lipid modification

Evidence reviews

The following document contains the evidence that was used to develop the December 2023 recommendations:

• Escalation of lipid-lowering treatment for secondary prevention of CVD

The following documents contain the evidence that was used to develop the May 2023 recommendations:

• CVD risk assessment tools: primary prevention
• Dietary cholesterol strategies
• Statins: efficacy and adverse effects

These documents preserve evidence reviews and committee discussions for areas of the guideline before 2023:

• Full guideline
• Appendices

Other supporting evidence

• Methods for evidence reviews A to C
• Methods for evidence review D
• Cost-utitlity analysis
• Network meta-analysis